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Floyd ZE, Segura BM, He F, Stephens JM. Degradation of
STAT5 proteins in 3T3-L1 adipocytes is induced by TNF- and
cycloheximide in a manner independent of STAT5A activation. Am J
Physiol Endocrinol Metab 292: E461–E468, 2007. First published
September 19, 2006; doi:10.1152/ajpendo.00334.2006.—Tumor ne-
crosis factor- (TNF-) is a multifunctional cytokine that has been
implicated as a causative factor in obesity-linked insulin resistance. It
is commonly accepted that macrophage-derived TNF- acts in a
paracrine manner on adjacent adipocytes to inhibit the expression of
various adipocyte genes and to attenuate insulin signaling. Several
studies have revealed that signal transducer and activator of transcrip-
tion (STAT)5 proteins are modulated during adipogenesis and can
modulate the transcription of some adipocyte genes. In this study, we
demonstrate that TNF- treatment, in the presence of cycloheximide,
also results in the rapid turnover of STAT5A and STAT5B in a
process that is independent of STAT5 activation by tyrosine phos-
phorylation. In addition, STAT5B is more labile than STAT5A under
these conditions, suggesting that the COOH terminus of STAT5 may
be involved in the turnover of each protein. Initial characterization of
the TNF- and cycloheximide-mediated degradation of STAT5 indi-
cates that inhibition of the proteasome stabilizes both forms of STAT5
in the presence of TNF-. In addition, the use of an NF-B inhibitor
results in the stabilization of STAT5A in the presence of TNF- and
cycloheximide, indicating that the degradation of STAT5 proteins
under these conditions may involve the NF-B pathway. STAT5
proteins are abundantly expressed in mature adipocytes and are
normally extremely stable proteins under a wide range of conditions.
However, our results demonstrate that the potentiation of TNF--
mediated signaling in the presence of cyclohexmide is associated with
a significant increase in the degradation of STAT5 proteins in 3T3-L1
adipocytes.
signal transducer and activator of transcription-5; tumor necrosis
factor-; proteasome; nuclear factor-B
THE SIGNAL TRANSDUCER AND ACTIVATOR of transcription (STAT)
family of proteins are central regulators of cytokine-mediated
signaling events in cell growth and differentiation. STAT
proteins are latent transcription factors that are activated
through tyrosine phosphorylation via interactions with cyto-
kine receptor-associated Janus tyrosine kinases (JAK) or
growth factor receptor tyrosine kinases (22). STAT5A and
STAT5B are activated by growth hormone-mediated signaling
and are highly induced during adipogenesis. A number of
studies indicate that STAT5 proteins are important in adipocyte
function (10, 30, 38). Evidence that STAT5 proteins play a role
in adipocytes includes studies demonstrating that ectopic ex-
pression of STAT5A confers adipogenesis in nonprecursor cell
lines (10), expression of a dominant-negative form of STAT5
inhibits lipid accumulation during adipogenesis (33), and con-
stitutively active STAT5 can replace the requirement for
growth hormone in adipogenesis (40).
TNF- is a multifunctional cytokine that is highly expressed
in adipose tissue and contributes to the development of insulin
resistance associated with obesity (reviewed in Refs. 18, 36).
Although the mechanism of TNF--mediated insulin resistance
is not entirely understood, TNF- treatment results in the
downregulation of a range of genes required for insulin sig-
naling, including GLUT4, insulin receptor (IR), insulin recep-
tor substrate-1 (IRS-1) (35, 39), and the protein kinase Akt (7).
A recent study suggests that NF-B activation is required for a
variety of effects that TNF- has on adipocytes (35).
In the present study, we present evidence that, in the pres-
ence of cycloheximide, TNF- mediates a substantial down-
regulation of STAT5 proteins in adipocytes via a pathway that
appears to involve NF-B and leads to the destabilization of
STAT5A and STAT5B proteins. The TNF--mediated in-
creased turnover of STAT5 is dependent on the presence of
cycloheximide under acute or chronic conditions, indicating
that potentiation of TNF- signaling in adipocytes is associated
with decreased expression of STAT5 proteins. Other studies
have shown that TNF- mediates decreases in Akt protein
levels in adipocytes, an effect that is also enhanced in the
presence of cycloheximide (25). Taken together, these studies
indicate that TNF-, in addition to regulating gene expression
at the transcriptional level, also regulates the degradation of
proteins in adipocytes. Destabilization of adipocyte proteins
via TNF--dependent mechanisms in adipocytes may represent
an additional pathway involved in the development of insulin
resistance associated with obesity.
MATERIALS AND METHODS
Materials. Dulbecco’s modified Eagle’s medium (DMEM) was
purchased from Life Technologies. Bovine and fetal bovine serums
(FBS) were obtained from Sigma and Life Technologies, respectively.
Murine TNF- was purchased from Biosource International. Cyclo-
heximide, wortmannin, N-p-tosyl-L-phenylalanine chloromethyl ke-
tone (TPCK), growth hormone, insulin, and U-0126 were purchased
from Sigma. MG-132 was obtained from Boston Biochem. The
non-phospho-STAT antibodies were a mouse monoclonal antibody
purchased from Transduction Laboratories (STAT5B) and a rabbit
polyclonal antibody from Santa Cruz Biotechnology (STAT5A). A
highly phospho-specific polyclonal antibody for STAT5 (Y694) was
purchased from Upstate Biotechnologies.
Cell culture. Murine 3T3-L1 preadipocytes were plated and grown
to 2 days postconfluence in DMEM with 10% bovine serum. Medium
was changed every 48 h. Cells were induced to differentiate by having
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the medium changed to DMEM containing a standard induction
cocktail of 10% FBS, 0.5 mM 3-isobutyl-1-methylxanthine, 1 M
dexamethasone, and 1.7 M insulin (MDI). After 48 h, this medium
was replaced with DMEM supplemented with 10% FBS, and cells
were maintained in this medium.
Preparation of whole cell extracts. Cell monolayers were rinsed
with phosphate-buffered saline and harvested in a nondenaturing
buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA,
1 mM EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 M PMSF, 1
M pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 M
leupeptin, and 2 mM sodium vanadate. Samples were extracted for 30
min on ice and centrifuged at 15,000 rpm at 4°C for 15 min.
Supernatants containing whole cell extracts were analyzed for protein
concentrations using a bicinchoninic acid kit (Pierce) according to the
manufacturer’s instructions.
Nuclear and cytoplasmic fractionation. Cell monolayers were
rinsed with phosphate-buffered saline and harvested in a nuclear
homogenization buffer containing 20 mM Tris (pH 7.4), 10 mM NaCl,
and 3 mM MgCl2. Nonidet P-40 was added to a final concentration of
0.15%, and cells were homogenized with 16 strokes in a Dounce
homogenizer. Homogenates were centrifuged to obtain nuclear and
cytoplasmic extracts. Nuclear extracts were suspended in a non-
denaturing buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 1
mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1
M phenylmethylsulfonyl fluoride, 1 M pepstatin, 50 trypsin inhib-
itory milliunits of aprotinin, 10 M leupeptin, and 2 mM sodium
vanadate. Triton X-100 was added to cytoplasmic extracts to a final
concentration of 1%.
TNF- and growth hormone treatment of 3T3-L1 adipocytes.
TNF- (5 nM) was added to developing or fully differentiated 3T3-L1
adipocytes for the indicated times. Growth hormone (250 ng/ml) was
added as indicated. Cycloheximide (5 M) was present in experi-
ments examining the effect of TNF- or growth hormone on STAT5
half-life. The adipocytes were incubated with a panel of inhibitors (10
M MG-132, 5 M U-0126, 200 nM wortmannin, or 10 M TPCK)
in experiments designed to characterize the mechanism of STAT5
turnover. STAT5 (5A and 5B) and STAT5-phosphotyrosine expres-
sion was analyzed by Western blot analysis.
Gel electrophoresis and immunoblotting. Proteins were separated
in 7.5% polyacrylamide (National Diagnostics) gels containing SDS,
as previously described (10), and transferred to nitrocellulose (Bio-
Rad) in 25 mM Tris, 192 mM glycine, and 20% methanol. Following
transfer, the membrane was blocked in 4% milk for 1 h at room
temperature. Results were visualized with horseradish peroxidase-
conjugated secondary antibodies (Sigma) and enhanced chemilumi-
nescence (Pierce).
Half-life determinations. Un-Scan-It version 5.1 (Silk Scientific)
was used to quantify Western blot data for STAT5A and STAT5B
obtained under control and TNF--treated conditions. Each experi-
ment was performed three times independently, and the average and
SD are reported for each condition.
RESULTS
TNF- treatment destabilizes STAT5A in fully differentiated
3T3-L1 adipocytes. Several recent studies have shown that
STAT5 proteins play an important role in adipogenesis (10, 30,
33). We demonstrated that STAT5A, but not STAT5B, expres-
sion is sufficient to promote adipogenesis in non-precursor
cells (10). Although STAT5B alone is not adipogenic, expres-
sion of STAT5B does enhance the adipogenic potential of
STAT5A. In the course of examining the regulation of STAT5
in fully differentiated adipocytes, we noted that exposure to
cycloheximide only resulted in a loss of STAT5A protein
expression when TNF- was present (Fig. 1A). The levels of
extracellular signal-regulated kinase (ERK)1 were examined to
confirm even loading of protein extracts (data not shown). To
determine whether the effect was specific for TNF-, we
examined the expression of STAT5 proteins following treat-
ment with cyclohexmide and other cytokines that modulate
adipocyte gene expression. As shown in Fig. 1B, the steady-
state levels of STAT5A were undetectable in the presence of
TNF- and cycloheximide. However, the presence of cyclo-
heximide with either growth hormone, oncostatin M, or car-
diotrophin-1 did not affect STAT5 protein levels under these
conditions. The levels of ERK1 are shown to indicate even
loading of protein extracts. The cells do not appear to be
undergoing apoptosis, as has been reported for TNF--medi-
ated effects in the presence of cycloheximide (32, 49), since the
levels of ERK1 protein were unchanged.
We also determined the location(s) of STAT5 turnover. The
results in Fig. 2 indicate that the loss of STAT5A was not
limited to the cytoplasm. When STAT5 levels in fully differ-
entiated 3T3-L1 adipocytes are measured without serum de-
privation, substantial amounts of STAT5A are found in the
nucleus, possibly due to the presence of growth hormone in the
serum (40). Our measurements of TNF--mediated STAT5A
turnover in cytoplasm and nuclear fractions show that both
populations of STAT5A proteins are destabilized in the pres-
ence of TNF- and cycloheximide. Even loading of protein
extracts was confirmed (data not shown).
Fig. 1. TNF- treatment in the presence of cycloheximide (CH) destabilizes
signal transducer and activator of transcription (STAT)5A in fully differenti-
ated 3T3-L1 adipocytes. A: fully differentiated 3T3-L1 adipocytes were treated
with 5 M CH in the presence (TNF-) or absence (control) of 5 nM TNF-
and harvested at the indicated time points. B: fully differentiated 3T3-L1
preadipocytes were treated with TNF- (TNF, 2 nM), growth hormone (GH,
250 ng/ml), oncostatin M (OSM, 0.5 ng/ml), or cardiotropin-1 (CT-1, 0.2 nM)
for 6 h in the presence of 5 M CH. Whole cell extracts were harvested after
6 h. In each experiment, 100 g of each extract were separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis using
anti-STAT5A, anti-STAT3, anti-STAT5B, or anti-extracellular signal-regu-
lated kinase (ERK)1 antibodies and visualized with horseradish peroxidase
(HRP)-conjugated secondary antibodies and chemiluminescence. This is a
representative experiment independently performed 3 times.
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TNF- does not activate STAT5A or affect growth hormone-
mediated STAT5A activation. Previous studies indicating that
TNF- induces phosphorylation of STAT5A in the rat hypo-
thalamus and liver (34), as well as in 3T3-L1 adipocytes (14),
prompted us to determine whether TNF--mediated turnover
of STAT5A was related to activation of STAT5 via tyrosine
phosphorylation. Hence, we examined the growth hormone-
induced activation of STAT5 tyrosine phosphorylation in the
absence or presence of various TNF- pretreatments. As
shown in lane 2 of Fig. 3A, growth hormone induced the
tyrosine phosphorylation of STAT5 proteins. However, a 15-
min treatment with TNF- (lane 3) did not induce STAT5
activation. Moreover, none of the TNF- pretreatments
(0.25–2 h) of mature 3T3-L1 adipocytes resulted in the acti-
vation of STAT5 in our studies. In addition, pretreatment with
TNF- did not affect growth hormone-dependent activation of
STAT5. We also examined the ability of TNF- to affect
growth hormone-induced STAT5 activation in the presence of
cycloheximide. As shown in Fig. 3B, a 6-h TNF- treatment
did not attenuate the ability of acute growth hormone to induce
STAT5 phosphorylation. However, a 6-h treatment of both
TNF- and cycloheximide was accompanied by a substantial
loss of STAT5A levels and a decrease in growth hormone-
induced STAT5A activation, consistent with the decreased
levels of STAT5A total protein. Yet these data demonstrate
that the STAT5A can still be activated by growth hormone in
the presence of cycloheximide (lane 6), indicating that TNF-
is not inducing STAT5A degradation in a manner associated
with STAT5 phosphorylation. The levels of ERK1 are shown
to indicate even loading of protein extracts. In summary, the
results suggest that cyclohexmide and TNF- affect STAT5A
turnover, independent of transcriptional activation of STAT-
5A, which is modulated by its tyrosine phosphorylation.
To further examine this question, we examined the ability of
growth hormone to affect the decay of STAT5 proteins. The
results in Fig. 4 demonstrate that growth hormone does not
affect STAT5A (Fig. 4A) or STAT5B (Fig. 4B) stability,
suggesting that activation of STAT5 proteins is unrelated to the
increased turnover observed in the presence of TNF-. More-
over, growth hormone does not rescue the TNF--induced
destabilization of STAT5 proteins (Fig. 4), indicating that
TNF- and growth hormone are independent regulators of
STAT5 proteins in cultured adipocytes.
STAT5B is more labile than STAT5A under TNF--mediated
conditions in 3T3-L1 adipocytes. The TNF--mediated desta-
bilization of STAT5A in the presence of cycloheximide may be
specific for STAT5A or also affect the highly homologous
STAT5B, which is encoded by a separate gene (24). Previous
studies have shown that tyrosine-phosphorylated STAT5 is
targeted to the proteasome via the carboxy terminal region of
STAT5 that overlaps the transcriptional activation domain
(44). STAT5A and STAT5B differ at the carboxy terminal
region, and we carried out experiments to examine the stability
of STAT5B protein in the presence of TNF- and cyclohexi-
mide. In several independent experiments, we observed that the
half-lives of STAT5A (23.8  3.8 h) and STAT5B (24 
3.3 h) were very similar under basal conditions (cycloheximide
treatment alone) in 3T3-L1 adipocytes. However, in the pres-
ence of TNF- and cycloheximide, STAT5B was notably more
labile, with a half-life of 0.73  0.07 h compared with
STAT5A (1.5  0.38 h). These studies demonstrate that
TNF- has a substantial effect on the degradation of both
STAT5A and STAT5B in adipocytes. In addition, our half-life
determinations clearly indicate that STAT5B becomes signif-
icantly more unstable than STAT5A in the presence of TNF-
Fig. 3. TNF- does not activate STAT5A or affect GH-induced STAT5A
activation. A: fully differentiated 3T3-L1 adipocytes were pretreated with 5 nM
TNF- for the indicated times before 15-min incubation with 250 ng/ml GH.
B: mature 3T3-L1 adipocytes were incubated for 6 h in the presence of 5 M
CH [control (CTL)] alone, 5 nM TNF- (TNF) alone, or TNF- and CH
combined (TNF-  CH) before incubation in the absence or presence of GH
(250 ng/ml) for 10 min. For A and B, whole cell extracts were harvested, and
100 g of each extract were separated by SDS-PAGE followed by transfer to
nitrocellulose. The samples were assayed by Western blot analysis using
anti-STAT5A, anti-STAT5-phosphotyrosine (STAT5PY), or anti-ERK1/2 an-
tibodies. This is a representative experiment independently performed 3 times.
Fig. 2. Cytoplasmic and nuclear STAT5A proteins are destabilized by TNF-.
Fully differentiated 3T3-L1 adipocytes were treated with 5 M CH for the
indicated time in the presence (TNF-) or absence (control) of 5 nM TNF-.
Extracts were fractionated into cytoplasmic and nuclear components, as de-
scribed in MATERIALS AND METHODS, and 100 g of each extract were separated
by SDS-PAGE. Following transfer to nitrocellulose, the samples were ana-
lyzed by Western blotting using an anti-STAT5A antibody. The experiment
was carried out in triplicate and performed independently twice.
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and cycloheximide. Also, the more rapid degradation of
STAT5B is evident in Fig. 4B.
TNF--mediated turnover of STAT5A is affected by NF-B
activity and proteasome activity but is independent of ERK1/2
kinase, p38 MAPK, or phosphatidylinositol 3-kinase. TNF--
mediated signaling involves several pathways, including the
p38 and ERK1/2 mitogen-activated kinase pathways (31, 47),
as well as the NF-B pathway (2). We used a range of
signaling inhibitors to determine whether these pathways are
involved in the TNF--mediated turnover of STAT5A. As
shown in Fig. 5A, a 1-h pretreatment of fully differentiated
3T3-L1 adipocytes with the MEK inhibitor U-0126 (5 M) or
the p38 MAPK inhibitor SB-203580 (10 M) did not signifi-
cantly affect the degradation of STAT5A induced by the
presence of TNF-. Indeed, pretreatment with the p38 MAPK
inhibitor was associated with a slight increase in the TNF--
mediated turnover of STAT5. These results indicate that TNF-
-mediated destabilization of STAT5A is independent of these
MAPK signaling pathways. Given the role of the phosphati-
dylinositol 3-kinase (PI3K)/Akt pathway in insulin signaling in
adipocytes (reviewed in Ref. 41) and the effects of TNF- on
insulin sensitivity, we next examined the role of the PI3K/Akt
pathway in TNF--mediated STAT5A turnover. The results in
Fig. 5B demonstrate that inhibition of PI3K signaling with a
1-h pretreatment with wortmannin (200 nM) does not affect
TNF--induced STAT5 turnover. The efficacy of the wortman-
nin is demonstrated by its ability to inhibit insulin-induced Akt
phosphorylation. Similar experiments were conducted to con-
firm the efficacy of each inhibitor (data not shown). Although
inhibition of ERK1 and ERK2, p38 MAPKs, or PI3K did not
affect the ability of TNF- to modulate STAT5 degradation,
we did observe a role of the NF-B pathway. Inhibition of
NF-B activation using the serine protease inhibitor TPCK (10
M) (16) resulted in the stabilization of STAT5A in the
presence of TNF- (Fig. 5C). These observations are consis-
tent with other studies indicating that NF-B activation by
TNF- is required for a wide range of TNF- effects on
3T3-L1 adipocytes (35). Since NF-B activation occurs via the
proteasome-dependent degradation of inhibitory factor IB-
(16), we examined the turnover of STAT5A in the presence of
the 20S proteasome inhibitor MG-132 (10 M) (21). As shown
in Fig. 5D, inhibition of the 20S proteasome stabilized
STAT5A compared with TNF--mediated turnover of
STAT5A in the presence of MEK inhibition. However, it is
interesting to note that neither TPCK nor MG-132 completely
reversed the effects of TNF-, suggesting that additional sig-
naling pathways are involved in this process. For each exper-
iment in Fig. 5, the levels of ERK1 were examined to confirm
even loading of protein extracts (data not shown).
DISCUSSION
It is well established that chronic TNF- treatment of
3T3-L1 adipocytes results in insulin resistance, and various
mechanisms for TNF--mediated insulin resistance have been
described (reviewed in Refs. 18, 36, 46). Microarray studies
have demonstrated that TNF- treatment (4–24 h) of 3T3-L1
adipocytes mediates the suppression of a range of genes re-
quired for insulin sensitivity (35). The decrease in gene ex-
pression is accompanied by a decrease in the protein levels of
several proteins involved in insulin signaling, confirming an
earlier study demonstrating that long-term exposure to TNF-
is associated with a loss of IRS-1 and GLUT4 proteins in
3T3-L1 adipocytes (39). In addition, TNF- also mediates the
loss in the levels of the IR and Akt (6), possibly as a result of
downregulation of gene expression in the 3T3-L1 adipocytes
(35). In our present study, we observed that TNF- inhibited
the expression of STAT5A, a transcription factor that is im-
portant in fat cells (10, 30, 38, 40). However, the TNF--
mediated changes in gene expression did not identify changes
in STAT5 mRNA expression, suggesting that the decrease in
STAT5 protein that we observed in the presence of TNF- and
cycloheximide is mediated by posttranslational mechanisms.
Our studies demonstrate that TNF- treatment resulted in a
rapid destabilization of both STAT5A and STAT5B proteins in
cultured adipocytes. Although STAT5B was more labile than
STAT5A, the significance of this observation is not known, as
both of these proteins respond similarly to TNF- and growth
hormone treatment. However, there is evidence that these
Fig. 4. GH-induced STAT5 phosphorylation does not destabilize STAT5 and
does not affect the CH and TNF--induced degradation of STAT5. Fully
differentiated 3T3-L1 adipocytes were treated with 5 M CH in the absence
(control) or presence of 5 nM TNF-, 250 ng/ml GH, or both TNF- and GH
(GH/TNF-). Whole cell extracts were harvested at the indicated time points,
and 100 g of each extract were separated by SDS-PAGE, followed by transfer
to nitrocellulose and analysis by Western blotting using anti-STAT5A anti-
body (A) or anti-STAT5B antibody (B). Each experiment was carried out in
triplicate and performed independently twice.
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proteins can have nonredundant functions and, hence, may be
differentially regulated. The degradation of STAT5 proteins
occurred in both the cytosol and nucleus. As shown in Fig. 2,
a substantial loss of STAT5A proteins was observed in both the
cytosol and nucleus following treatment with TNF- and
cycloheximide. In the cytosolic extracts, reduced levels of
STAT5A were also observed following 6- and 8-h treatments.
In the nuclear extracts, STAT5A was absent at these time
points. We hypothesize that these observations are not medi-
ated by major differences in the kinetic decay profile between
nucleus and cytoplasm. We predict that the more rapid loss of
STAT5A in the nucleus is due to the fact that there is more
STAT5A protein in the nucleus than in the cytosol under the
conditions studied in Fig. 2. Hence, it appears to disappear
quicker in the location. All of our results suggest that the decay
of STAT5A proteins is similar in the cytosol and the nucleus.
Moreover, these observations are strongly supported by data in
Fig. 4, demonstrating that activation of STAT5A by growth
hormone (which results in an increase in nuclear STAT5A)
does not affect the decay of STAT5A, nor does it affect the
ability or timing of the TNF--induced degradation of
STAT5A.
TNF--mediated insulin resistance is reported to involve
regulation of posttranslational modifications of proteins re-
quired for insulin signaling, such as altering the phosphoryla-
tion status of the IR and IRS-1 (8, 13, 19, 20). A number of
signaling pathways are important in TNF--mediated re-
sponses in adipocytes that lead to insulin resistance. Among
these are the p42/44 (ERK1/2) MAPK (5), p38 MAPK (37),
and NF-B (35, 36) pathways. ERK1/2 activity plays a role in
TNF--mediated serine/threonine phosphorylation of IRS-1,
and inhibition of ERK1/2 activity restores insulin sensitivity in
the presence of TNF- (5, 11). A role for p38 MAPK activa-
tion in TNF--induced insulin resistance has been demon-
strated in brown adipocytes (17), as well as human adipocytes
(3), although the contribution is considered to be less pro-
Fig. 5. TNF- and CH-induced STAT5A degradation is modulated by the proteasome and NF-B activity, but not ERK1/2, p38 MAPK, or phosphatidylinositol
3-kinase activity. A: fully differentiated 3T3-L1 adipocytes were pretreated with 5 M U-0126 (MEK inhibitor) or 10 M SB-203580 (p38 inhibitor) 1 h before
5 nM TNF- and 5 M CH were added. In addition, adipocytes were pretreated with 200 nM wortmannin (phosphatidylinositol 3-kinase inhibitor); B), 10 M
N-p-tosyl-L-phenylalanine chloromethyl ketone (TPCK; NF-B activation inhibitor; C), or 10 M MG-132 (20S proteasome inhibitor; D). Whole cell extracts
were harvested, and 100 g of each extract were separated by SDS-PAGE and subjected to Western blot analysis using anti-STAT5A antibody. In each case,
STAT5A turnover was examined in the presence of the indicated inhibitor plus TNF- and was compared with the turnover rate in the absence (control) or
presence of TNF- alone. Each experiment was carried out in triplicate and performed twice independently.
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nounced than the effect mediated by the ERK1/2 pathway (11,
37). Indeed, additional studies in brown adipocytes have indi-
cated that inhibition of p38 MAPK, in contrast to ERK1/2,
potentiates the negative effect of TNF- on insulin signaling
(43). The NF-B pathway also plays a central role in TNF--
induced insulin resistance in adipocytes, mediating the regula-
tion of a range of factors, including IR, IRS-1, and the Akt
protein kinase B (35, 36). Interestingly, a number of studies
show that TNF- stimulates Akt phosphorylation in an NF-
B-dependent manner (26, 27). In addition, TNF--induced
NF-B activity is independent of ERK1/2 and p38 MAPK
activity in brown adipocytes (42), suggesting that TNF- may
exert effects on insulin sensitivity independently of ERK1/2
and p38 MAPK activity. In support of this notion, TNF-
regulation of resistin, an adipokine associated with insulin
resistance, is independent of ERK1/2 and p38 activation in
3T3-L1 adipocytes (6).
Our results indicate that TNF- also mediates the turnover
of STAT5 proteins in adipocytes in a manner that is influenced
by NF-B activity, but clearly independent of ERK1/2 and p38
MAPK activation or phosphorylation of Akt. However, it is
interesting to note that inhibition of p38 activity has a modest
effect on TNF--mediated STAT5 turnover, and inhibition of
ERK1/2 had no effect on this process. These data are in
agreement with previous studies showing that the ERK1/2 and
p38 signaling pathways do not play equivalent roles in TNF-
-mediated insulin resistance (23, 24). To our knowledge, this
is the first report of TNF--mediated destabilization of STAT5
proteins in adipocytes. Our results indicate that TNF- induces
a significantly accelerated decay rate for STAT5 in 3T3-L1
adipocytes that is influenced by activity of the NF-B pathway.
Although NF-B activation is well known to depend on pro-
teasome activity via degradation of inhibitory factor IB-
(16), STAT5 is also a known substrate of the 26S proteasome
(44). The observed changes in the decay rates for STAT5A and
STAT5B are pronounced, and the usually abundant and stable
STAT5 proteins (23- to 24-h half-lives) are converted to highly
unstable proteins with half-lives reduced to 90 and 44 min,
respectively. These changes in stability of the STAT5 proteins
suggest that TNF--mediated activation of NF-B may alter
26S proteasome recognition of the STAT5 proteins in adipo-
cytes in a manner that is independent of STAT5 tyrosine
phosphorylation.
The present results suggest that a protein that is modified by
TNF- signaling mediates the degradation of STAT5 proteins
in adipocytes. However, TNF-/NF-B-mediated destabiliza-
tion of STAT5 in 3T3-L1 adipocytes appears to be unrelated to
growth hormone-induced activation of STAT5 proteins via
tyrosine phosphorylation. Moreover, growth hormone activa-
tion of STAT5 does not alter STAT5 protein stability. Al-
though TNF- and growth hormone activate phosphorylation
of JAK2 (7), the minimal levels of TNF--induced STAT5
phosphorylation in our experiments suggests that JAK2 recep-
tors are not involved in the TNF--dependent destabilization of
STAT5. In addition, the low level of STAT5 tyrosine phos-
phorylation associated with TNF- treatment also suggests that
dephosphorylation mediated by the PTP-1B cytoplasmic phos-
phatase is unlikely to be involved in this process. Nonetheless,
there are intriguing possibilities for factors that may be in-
volved in the accelerated degradation of STAT5. One of these
is the suppressor of cytokine signaling (SOCS) family of
adapter proteins that act as negative regulators of cytokine
signaling by targeting substrates to the ubiquitin-proteasome
system (reviewed in Ref. 48). Both TNF- and growth hor-
mone stimulate an increase in SOCS-1 and SOCS-3, resulting
in the downregulation of JAK/STAT pathways through inter-
actions with the phosphorylated JAK2 receptor (7). However,
our studies argue against a role for SOCS adaptors in the
destabilization of STAT5 due to the differential effects of
growth hormone and TNF- and recent studies by our labora-
tory demonstrating that expression of SOCS-3 does not induce
IRS-1 degradation in adipocytes (15). Another interesting pos-
sibility is c-Cbl, a cytoplasmic protein that functions as a
ubiquitin ligase to target substrates for degradation and has
been shown to maybe play a role in regulating insulin sensi-
tivity in adipocytes (23, 29). Recent studies in NIH 3T3 cells
show that c-Cbl downregulates growth hormone-stimulated
STAT5 activity by targeting STAT5 to the proteasome (12).
These studies are similar to our results in that c-Cbl targets
STAT5 for degradation independently of JAK2 or STAT5
phosphorylation and does not depend on translocation of
STAT5 to the nucleus. Although our present studies do not
address this issue, other studies have demonstrated that c-Cbl
participates in signaling mediated by the TNF- family of
proteins (1).
It is important to note that our findings occur in the context
of TNF- signaling in the presence of cycloheximide. Al-
though the presence of 5 M cycloheximide in this study did
not result in substantial morphological changes indicative of
apoptosis, the combination of TNF- and cycloheximide has
been associated with potentiation of TNF- effects in a range
of cell types (9, 28, 32, 49). Indeed, our studies in 3T3-L1
adipocytes are consistent with an earlier study indicating that
human fat cells are rendered significantly more sensitive to the
effects of TNF- in the presence of cycloheximide (9). Inter-
estingly, inhibition of TNF--induced apoptosis in human fat
cells depends on the IGF-I (9), and growth hormone stimula-
tion of IGF-I expression is mediated by STAT5 (4, 45).
Taken together, these studies demonstrate that potentiation
of TNF- signaling significantly influences the stability of
STAT5 proteins in adipocytes in a manner that correlates with
NF-B activation. These data represent an additional pathway
that TNF- uses to alter expression levels of important adipo-
cyte proteins such as STAT5A. In addition, destabilization of
the unphosphorylated STAT5 proteins via the TNF- pathway
indicates that the STAT5 proteins are regulated in the cyto-
plasm of fat cells in a manner that is independent of their
activation and function as transcription factors. STAT proteins
are found in cytoplasmic multisubunit complexes that may
serve as platforms for STAT protein interactions (reviewed in
Ref. 22), and regulating the levels of STAT5 in these com-
plexes may play a role in insulin signaling in adipocytes. In
summary, our studies reveal that STAT5 proteins can be
significantly regulated by altering their half-lives in a manner
that is independent of their presence in the nucleus.
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